ENTITY
Laekna

Laekna (2105 HK)

36
Analysis
Health Care • China
Laekna is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer, metabolic diseases, and liver fibrosis. Its pipeline includes drug candidates such as LAE002 for breast and prostate cancer, LAE001 for prostate cancer, and LAE102 for obesity. The company was founded in 2016 and is headquartered in Yuyao, China.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x